DEL_Basilea Pharmaceutica ((DEL_0QNA)), Basilea Pharmaceutica ((CH:BSLN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 study titled ‘An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections.’ The study aims to evaluate the efficacy and safety of fosmanogepix for treating invasive mold infections, a significant concern due to the rising cases of multidrug-resistant molds.
Intervention/Treatment: The study tests fosmanogepix, administered either intravenously or orally, as a treatment for invasive mold infections. The drug is intended to offer an effective alternative to standard antifungal therapies.
Study Design: This open-label, randomized study involves two cohorts. Cohort A compares fosmanogepix with standard antifungal treatments, while Cohort B administers fosmanogepix to patients who did not respond to previous treatments. The primary goal is to assess all-cause mortality by Day 42.
Study Timeline: The study began in August 2025, with primary completion expected in 2025. The last update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study’s progress could impact Basilea Pharmaceutica’s stock performance positively, as successful results may position fosmanogepix as a leading treatment for invasive mold infections. Investors should monitor competitor developments in antifungal treatments, as advancements could influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.